Trials / Recruiting
RecruitingNCT06464861
Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
Sequential Treatment With 7x19 CAR-T After Umbilical Cord Blood Derived CD19 CARNK in Relapsed/Refractory B Cell Lymphoma
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (estimated)
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To study the safety and efficacy of cord blood-derived CD19 CAR-NK cells sequential with 7x19 CAR-T in relapse / refractory B cell lymphoma
Detailed description
This is a single-center, open, single-arm clinical exploratory study to observe the safety and efficacy of cord blood derived CD19 CAR-NK cells sequential treatment with 7x19 CAR-T in relapse / refractory B cell lymphoma. This study consisted of two phases: phase I: CARNK cells preparation and infusion (Day0, dose of 2 x 10\^6 / kg). Phase II: 7x19 CAR-T cells preparation and infusion (Day7, dose 2×10\^6/kg).
Conditions
- Primary Mediastinal B-cell Lymphoma (PMBCL)
- Mantle Cell Lymphoma (MCL)
- Diffuse Large B Cell Lymphoma( DLBCL)
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CD19-CAR-NK/T | Cord blood derived CD19 CARNK sequential Treatment with 7x19 CAR-T |
Timeline
- Start date
- 2024-06-20
- Primary completion
- 2026-06-30
- Completion
- 2027-06-30
- First posted
- 2024-06-18
- Last updated
- 2025-02-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06464861. Inclusion in this directory is not an endorsement.